Benzylpiperazine: a drug of abuse?

No Thumbnail Available
File version
Author(s)
Johnstone, Alice C.
Lea, Rod A.
Brennan, Katie A.
Schenk, Susan
Kennedy, Martin A.
Fitzmaurice, Paul S.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2007
Size
File type(s)
Location
License
Abstract

N-benzylpiperazine (BZP) is the active ingredient in recreational 'party' or 'p.e.p.' pills, which are used to provide a stimulant, euphoric effect akin to that of methylenedioxymethamphetamine (MDMA, 'ecstasy'). BZP predominantly affects dopamine neurotransmission in a similar fashion to known 'drugs of abuse', such as methamphetamine and cocaine, which strongly suggests BZP has abuse liability. BZP is illegal in many countries including the United States of America and Australia, yet it remains legal in the United Kingdom, Canada and New Zealand. There has been little research, to date, on the neurological consequences of high dose or chronic exposure of BZP. Here we provide a comprehensive review of the information currently available on BZP and suggest a need for further research into the mechanisms of action, long-term effects and potentially addictive properties of BZP.

Journal Title

Journal of Psychopharmacology

Conference Title
Book Title
Edition
Volume

21

Issue

8

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Pharmacology and Pharmaceutical Sciences not elsewhere classified

Medical and Health Sciences

Psychology and Cognitive Sciences

Persistent link to this record
Citation
Collections